BMJ Open · 2019 · 10 citations · 21 references
PharmacyInfectious Disease ControlInfectious DiseasesHepatitis PharmacotherapyInfectious Disease PharmacotherapyPharmacovigilanceAntiviral TherapyInterferon-based TherapyTreatmentTreatment DurationViral HepatitisViral Hepatitis TreatmentAdherenceAdherence To InterventionBlood-borne VirusesHepatitis C ManagementPrimary Outcome AnalysisPsychological Predictors Of AdherenceViral Hepatitis Prevention
Introduction Hepatitis C is a blood-borne virus (HCV) that can seriously damage the liver and is spread mainly through blood-to-blood contact with an infected person. Over 85% of individuals who have HCV in Scotland became infected following injecting drug use. Since people who inject drugs (PWID) are the main source of new infections, theoretical modelling has suggested that treatment of HCV infection in PWID may effectively reduce HCV prevalence and accomplish elimination. This protocol describes a clinical trial delivering HCV treatment within injecting equipment provision sites (IEPS) in Tayside, Scotland. Methods and analysis PWID attending IEPS are tested for HCV and, if they are chronically infected with HCV and eligible, invited to receive treatment within the IEPS. They are randomised to one of three treatment regimens; daily observed treatment, treatment dispensed every 2 weeks and treatment dispensed every 2 weeks together with an adherence psychological intervention (administered before treatment begins). The primary outcome is comparison of the rate of successful treatment (SVR 12 ) in each treatment group. Secondary analyses include assessment of adherence, reinfection rates, viral resistance to treatment and interaction of the treatment with illicit drugs. Ethics and dissemination The ADVANCE (A Direct obserVed therApy versus fortNightly CollEction) HCV trial was given favourable opinion by East of Scotland Research Ethics Committee (LR/17/ES/0089) prior to commencement. Trial registration numbers European Clinical Trials Database (EudraCT) (2017-001039-38) and ClinicalTrials.gov ( NCT03236506 ).
21
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam H. Afdhal, Stefan Zeuzem, Paul Y. Kwo et al. · New England Journal of Medicine · 2014 · 1.7K citations · Full text
Julio Montaner, Viviane D. Lima, P. Richard Harrigan et al. · PLoS ONE · 2014 · 358 citations · Full text
Public Health, Infectious Disease Control, Preventive Medicine +16
Natasha K. Martin, Peter Vickerman, Graham R. Foster et al. · Journal of Hepatology · 2010 · 231 citations